Efficacy and Safety of Vildagliptin as an Add-on to Insulin with or without Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A 12-week, Double-Blind, Randomized Study
Takahisa Hirose, Manabu Suzuki, Isao Tsumiyama, Takahisa Hirose, Manabu Suzuki, Isao Tsumiyama
Abstract
Introduction: To assess the efficacy and safety of vildagliptin as add-on therapy in Japanese patients with type 2 diabetes mellitus (T2DM), inadequately controlled on stable long-acting, intermediate-acting, or pre-mixed insulin, with or without concomitant metformin.
Methods: In this 12-week placebo-controlled study, patients were randomized to receive either vildagliptin 50 mg twice daily (bid) or placebo treatment in a 1:1 ratio. The primary endpoint was change in glycated hemoglobin A1c (HbA1c) from baseline to 12-week endpoint. Secondary endpoints included proportion of patients achieving pre-defined HbA1c targets of ≤6.5%, <7.0%, and HbA1c <7.0% in patients with baseline HbA1c ≤8.0% and change in fasting plasma glucose (FPG) after 12 weeks of treatment. Regular monitoring was performed to record any treatment-emergent adverse events (AEs) and serious adverse events or hypoglycemic episodes.
Results: Of the 156 patients randomized, 96.8% completed the study (vildagliptin, n = 76; placebo, n = 75). Patient demographics and clinical characteristics were comparable between the groups at baseline. Addition of vildagliptin resulted in statistically significant reductions in HbA1c after 12 weeks (-1.01 ± 0.06%), with a between-treatment difference of -0.91 ± 0.09% (p < 0.001). FPG levels reduced from baseline to 12 weeks in the vildagliptin group (-1.2 ± 0.2 mmol/L), with a between-treatment difference of -1.2 ± 0.3 mmol/L which was significant (p < 0.001). The proportion of patients achieving HbA1c targets was higher with vildagliptin treatment for all pre-defined responder rate categories. The overall incidence of AEs was comparable between groups (vildagliptin, 46.2% vs. placebo, 43.6%). The overall incidence of hypoglycemic events was low and all events were self-treatable without using drug therapy. No severe hypoglycemic events were reported.
Conclusion: Treatment with vildagliptin 50 mg bid as add-on to insulin with or without metformin resulted in statistically significant reductions in HbA1c in Japanese patients with T2DM. Overall, vildagliptin was well tolerated with a safety profile similar to that of placebo in this patient population. ClinicalTrials.gov Identifier, NCT02002221 FUNDING: Novartis Pharma K.K.
Keywords: Hypoglycemia; Insulin; Japanese; Type 2 diabetes mellitus; Vildagliptin.
Figures
References
- International Diabetes Federation. IDF Diabetes Atlas. 6th ed. Brussels, Belgium: International Diabetes Federation, 2013. . Accessed 9 Jul 2015.
- Kawamori R. Diabetes trends in Japan. Diabetes Metab Res Rev. 2002;18:S9–S13. doi: 10.1002/dmrr.296.
- Neville SE, Boye KS, Montgomery WS, Iwamoto K, Okamura M, Hayes RP. Diabetes in Japan: a review of disease burden and approaches to treatment. Diabetes Metab Res Rev. 2009;25:705–716. doi: 10.1002/dmrr.1012.
- Namba M, Katsuno T, Kusunoki Y, Matsuo T, Miuchi M, Miyagawa J. New strategy for the treatment of type 2 diabetes mellitus with incretin-based therapy. Clin Exp Nephrol. 2012;17:10–15. doi: 10.1007/s10157-012-0709-0.
- Japan Diabetes Society. Treatment Guide for Diabetes. 2012–2013 Edited by Japan Diabetes Society. Bunkodo Co. Ltd. . Accessed 29 Jul 2015.
- Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia. 2012;55:1577–1596. doi: 10.1007/s00125-012-2534-0.
- Kadowaki T, Tajima N, Odawara M, Minamide T, Kawashima M, Yanagida D, et al. Efficacy and safety of sitagliptin add-on therapy in Japanese patients with type 2 diabetes on insulin monotherapy. Diabetol Int. 2013;4:160–172. doi: 10.1007/s13340-013-0109-z.
- Home P, Naggar NE, Khamseh M, Gonzalez-Galvez G, Shen C, Chakkarwar P, Yang W. An observational non interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries the A1chieve study. Diabetes Res Clin Pract. 2011;94:352–363. doi: 10.1016/j.diabres.2011.10.021.
- Mohamed M. An audit on diabetes management in Asian patients treated by specialists: the Diabcare-Asia 1998 and 2003 studies. Curr Med Res Opin. 2008;24:507–514. doi: 10.1185/030079908X261131.
- Noh RM, Graveling AJ, Frier BM. Medically minimizing the impact of hypoglycemia in type 2 diabetes: a review. Expert Opin Pharmacother. 2011;12:2161–2175. doi: 10.1517/14656566.2011.589835.
- Graveling AJ, Frier BM. Impaired awareness of hypoglycemia: a review. Diabetes Metab. 2010;36:S64–S74. doi: 10.1016/S1262-3636(10)70470-5.
- Oishi M, Yamazaki K, Okaguchi F, Sugimoto H, Kanatsuka A, Japan Diabetes Clinical Data Management Study Group Kashiwagi A Changes in oral antidiabetic prescriptions and improved glycemic control during the years 2002–2011 in Japan (JDDM32) J Diabetes Investig. 2014;5:581–587. doi: 10.1111/jdi.12183.
- Kothny W, Foley JE, Kozlovski P, Shao Q, Gallwitz B, Lukashevich V. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15:252–257. doi: 10.1111/dom.12020.
- Kozlovski P, Foley J, Shao Q, Lukashevich V, Kothny W. Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes. World J Diabetes. 2013;4:151–156. doi: 10.4239/wjd.v4.i4.151.
- Ning G, Wang W, Li L, Ma J, Lv X; all investigators, Yang M, Wang W, Woloschak M, Lukashevich V, Kothny W. Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus. J Diabetes. 2015. doi:10.1111/1753-0407.12303. (Epub ahead of print).
- Rosenstock J, Rendell MS, Gross JL, Fleck PR, Wilson CA, Mekki Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab. 2009;11:1145–1152. doi: 10.1111/j.1463-1326.2009.01124.x.
- Barnett AH, Charbonnel B, Donovan M, Fleming D, Chen R. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin. 2012;28:513–523. doi: 10.1185/03007995.2012.665046.
- Yki-Järvinen H, Rosenstock J, Durán-Garcia S, Pinnetti S, Bhattacharya S, Thiemann S, Patel S, Woerle HJ. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥ 52-week randomized, double-blind study. Diabetes Care. 2013;36:3875–3881. doi: 10.2337/dc12-2718.
- ADVANCE Collaborative Group. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572. doi: 10.1056/NEJMoa0802987.
- Action to Control Cardiovascular Risk in Diabetes Study Group. Gerstein HC, Miller ME, Byington RP, Goff DC, Jr, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–2559. doi: 10.1056/NEJMoa0802743.
- Ahrén B. Insulin plus incretin: a glucose-lowering strategy for type 2-diabetes. World J Diabetes. 2014;5:40–51. doi: 10.4239/wjd.v5.i1.40.
Source: PubMed